Top Markets
Coin of the day
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Rangering i aksjer #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Aksjekurs
$0.003084
Markedsverdi
$434.03K
Endring (1 dag)
-7.14%
Endring (1 år)
-89.24%
Land
BE
Handel Oxurion N.V. (OXUR)

Kategori

P/B-forhold for Oxurion N.V. (OXUR)
P/B-forhold per 2026 TTM: 0
Ifølge Oxurion N.V. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Oxurion N.V. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE